any chance for revival?-To The Moon - Tiger Brokers Online Investing Community - To The Moon

4
Comment
Favorite

Yeoster
2022-01-30

any chance for revival?

Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment

In solidarity with the selloff in the biotech space, Moderna has lost more than 41% YTD, becoming t

Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

4

Report

Comment

Top
Latest

lawteoh777
·2022-01-30
maybe.. or maybe not. lol. I have no conviction in vaccine stocks in the long term
Reply
Like
Report
Huatkor
·2022-01-30
Oh no.
Reply
Like
Report
ivy888
·2022-01-30
ok
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9093193565,"tweetId":"9093193565","gmtCreate":1643545327078,"gmtModify":1676533829933,"author":{"id":3578468403472437,"idStr":"3578468403472437","authorId":3578468403472437,"authorIdStr":"3578468403472437","name":"Yeoster","avatar":"https://static.tigerbbs.com/4f14d93223a91ecc512f0c06e6e6461c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>any chance for revival?</p></body></html>","htmlText":"<html><head></head><body><p>any chance for revival?</p></body></html>","text":"any chance for revival?","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9093193565","repostId":2207801110,"repostType":4,"repost":{"id":"2207801110","kind":"news","pubTimestamp":1643521816,"share":"https://www.laohu8.com/m/news/2207801110?lang=&edition=full","pubTime":"2022-01-30 13:50","market":"us","language":"en","title":"Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2207801110","media":"seekingalpha","summary":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming t","content":"<html><head></head><body><p>In solidarity with the selloff in the biotech space, <a href=\"https://laohu8.com/S/MRNA\">Moderna </a> has lost more than 41% YTD, becoming the sharpest decliner in the S&amp;P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.</p><p>With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.</p><p>Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.</p><p>While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.</p><p>However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-product company.</p><p>Meanwhile, <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer’s </a> partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Slips to Bottom of S&P 500 Amid Mixed Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Slips to Bottom of S&P 500 Amid Mixed Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 13:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 ...</p>\n\n<a href=\"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4504":"桥水持仓","MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/news/3793325-moderna-slips-to-bottom-of-sp-500-amid-mixed-sentiment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2207801110","content_text":"In solidarity with the selloff in the biotech space, Moderna  has lost more than 41% YTD, becoming the sharpest decliner in the S&P 500, notwithstanding a promising preannouncement on 2022 COVID-19 vaccine sales issued early this month.With its shares having lost more than two-thirds of the peak valuation in August, investors and analysts are becoming increasingly bullish on the prospects of Cambridge, MA-based firm. This month, two Seeking Alpha contributors issued back-to-back Buy recommendations on Moderna (MRNA) for the first time since November.Wall Street analysts seem to agree, as indicated in the rating history for the stock for the past month. An attractive valuation at current levels was the main driver for a recent upgrade at Deutsche Bank and a target hike at Bank of America.While Deutsche Bank noted that a possible transition of the pandemic to an endemic status would favor Moderna (MRNA), UBS analysts disagreed, warning that such an endgame to COVID-19 could hurt its prospects.However, the industry trajectory is not in Moderna’s (MRNA) favor. With the emergence of less severe Omicron, the projections for COVID-19 vaccine sales are likely to drop in 2022 from the previous year, according to a recent report by Airfinity. Yet, with a broad pipeline based on a proven platform and $17B in cash in the balance sheet, it won’t be long before Moderna (MRNA) transforms from a one-product company.Meanwhile, BioNTech , Pfizer’s  partner in COVID-19 vaccine development, is not much different except in terms of valuation. With Moderna (MRNA) trading at a 50% premium to the German vaccine maker’s current forward non-GAAP P/E ratio of ~4.0, the trading multiples of the two rivals indicate further downside for the U.S. company.","news_type":1},"isVote":1,"tweetType":1,"viewCount":362,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":100363280,"commentId":"100363280","gmtCreate":1643552679037,"gmtModify":1663242997427,"authorId":4093015537749630,"author":{"id":4093015537749630,"idStr":"4093015537749630","authorId":4093015537749630,"name":"lawteoh777","avatar":"https://static.tigerbbs.com/5ae1877cb7a2cdc2cf639fc280bc02e5","vip":1,"hat":"https://static.tigerbbs.com/3b7820dfed76481d8dc4de6ac5a7a136","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9093193565,"objectIdStr":"9093193565","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"maybe.. or maybe not. lol. I have no conviction in vaccine stocks in the long term","text":"maybe.. or maybe not. lol. I have no conviction in vaccine stocks in the long term","html":"maybe.. or maybe not. lol. I have no conviction in vaccine stocks in the long term","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":100362906,"commentId":"100362906","gmtCreate":1643548591033,"gmtModify":1663242998829,"authorId":3581919183376534,"author":{"id":3581919183376534,"idStr":"3581919183376534","authorId":3581919183376534,"name":"Huatkor","avatar":"https://static.tigerbbs.com/6f3897aace055b5fa9f58089c1e880d8","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9093193565,"objectIdStr":"9093193565","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Oh no. ","text":"Oh no. ","html":"Oh no. ","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":100362795,"commentId":"100362795","gmtCreate":1643546885247,"gmtModify":1663242996444,"authorId":3579641974902127,"author":{"id":3579641974902127,"idStr":"3579641974902127","authorId":3579641974902127,"name":"ivy888","avatar":"https://static.tigerbbs.com/10358949b7fc96b011ec29ca7fd9c9a4","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9093193565,"objectIdStr":"9093193565","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}